companydirectorylist.com  Global Business Directory e directory aziendali
Ricerca Società , Società , Industria :


elenchi dei paesi
USA Azienda Directories
Canada Business Elenchi
Australia Directories
Francia Impresa di elenchi
Italy Azienda Elenchi
Spagna Azienda Directories
Svizzera affari Elenchi
Austria Società Elenchi
Belgio Directories
Hong Kong Azienda Elenchi
Cina Business Elenchi
Taiwan Società Elenchi
Emirati Arabi Uniti Società Elenchi


settore Cataloghi
USA Industria Directories














  • Eli Lilly’s Obesity Pill Appears to Work as Well as Injected . . .
    New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and Ozempic for weight loss and lowering blood sugar
  • Study Suggests Weight-Loss Pill is as Effective as Ozempic
    The drugs in development include a pill that a new trial suggests is about as effective as Ozempic By Dani Blum Reporting from the American Diabetes Association Scientific Sessions in Chicago
  • New Weight Loss Pill Rivals Ozempic: What the Data Shows
    Among the most anticipated newcomers is a daily pill that early data suggests could be as powerful as the popular weekly injections currently on the market Reporting from the American Diabetes Association Scientific Sessions in Chicago, new findings presented this past weekend highlight just how potent these forthcoming weight loss drugs might be
  • Lilly Obesity Pill to Rival Shots Holds Up to Scrutiny in Trial
    The highest dose helped patients with type 2 diabetes lose 7 6% of their body weight, during the 40-week study, according to data presented Saturday at the American Diabetes Association conference
  • Lillys experimental obesity drug shows promise in early . . .
    The study enrolled 100 patients who were given different doses of the experimental drug or a placebo for 12 weeks Weight loss ranged from 2 6% to 11 3%, according to the abstract
  • Amycretin Shows Promise as Next-Gen Weight Loss Drug | First . . .
    Novo Nordisk has released results from early-stage trials from both the amycretin pill and injectable amycretin Data from the trial suggests that amycretin, a combination agonist of GLP-1 and amylin (a hormone that helps regulate blood sugar), was associated with a lower body weight after 12 weeks
  • New Obesity Pill Mimics Gastric Bypass Without Surgery
    Importantly, glucose tolerance tests revealed delayed uptake of glucose following SYNT-101 treatment At 30 and 60 minutes, glucose absorption was far lower than in untreated patients, by roughly 35% and 21%, respectively This delay suggests that absorption occurs later in the intestine, as expected, rather than in the coated region of the




Annuari commerciali , directory aziendali
Annuari commerciali , directory aziendali copyright ©2005-2012 
disclaimer